Risperidone: A Silver Lining In Mental Disorders

Nikita Gurav; Dhanshree Patil; Shweta Patil; Sayali Nejkar

doi:10.37591/rrjodfdp.v10i3.1375

Abstract

Risperidone (RYKINDO®) is second generation benzisothiazole which elevates linkage to serotonin type 2 (5HT2A) and dopamine type 2(D2) receptor developed by Luye Pharma Group used in short term palliative treatment of aggression or psychopathic disorders. Both 5HT2 antagonism with D2 receptor, it selectively bind to 5HT2A antagonist and shows neuroleptic effect by Risperidone. It is also available in the form of oral solution and disintegrating tablet etc. It is long acting injectable formulation approved atypical antipsychotic risperidone and used for treatment of schizophrenia and bipolar disorder in adult.On 15 January 2023, FDA accepted Risperidone for treatment of schizophrenia in grown up, and as mono treatment and augmentation therapy to lethane and valproic acid sodium salt for treatment of schizophrenia and bipolar disorder, it is an atypical antipsychotic drug injected one time every twice week. The U.S. FDA has approved Risperidone for extended release injectable suspension. Phase III development is underway worldwide. This article summarize different aspects of Risperidone as API used to improve mental health. For instance, it has been the subject of open clinical trials for the treatment of bipolar disorder, schizophrenia in youth, and as a monotherapy or adjunctive treatment to Lithane or Valproic acid sodium salt for the continuation of manic depression therapy. It is also used as an antipsychotic medication for the treatment of juvenile mental disorders, in children with neurodevelopmental disorders, and in children with attention deficit or hyperkinetic syndrome behavior disturbances. In another trial, risperidone was tested in 101 children with autism disorder; in this instance, risperidone improved irritability and autism-related behavioral disorders.

Abstract

Keywords